NO20001238D0 - Monoklonalt antistoff som induserer apoptose - Google Patents

Monoklonalt antistoff som induserer apoptose

Info

Publication number
NO20001238D0
NO20001238D0 NO20001238A NO20001238A NO20001238D0 NO 20001238 D0 NO20001238 D0 NO 20001238D0 NO 20001238 A NO20001238 A NO 20001238A NO 20001238 A NO20001238 A NO 20001238A NO 20001238 D0 NO20001238 D0 NO 20001238D0
Authority
NO
Norway
Prior art keywords
antibody
monoclonal antibody
associated proteins
human integrin
apoptosis
Prior art date
Application number
NO20001238A
Other languages
English (en)
Other versions
NO20001238L (no
Inventor
Naoshi Fukushima
Shinsuke Uno
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of NO20001238D0 publication Critical patent/NO20001238D0/no
Publication of NO20001238L publication Critical patent/NO20001238L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO20001238A 1997-09-11 2000-03-09 Monoklonalt antistoff som induserer apoptose NO20001238L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP26485397 1997-09-11
PCT/JP1998/004118 WO1999012973A1 (fr) 1997-09-11 1998-09-11 Anticorps monoclonal induisant l'apoptose

Publications (2)

Publication Number Publication Date
NO20001238D0 true NO20001238D0 (no) 2000-03-09
NO20001238L NO20001238L (no) 2000-05-11

Family

ID=17409137

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20001238A NO20001238L (no) 1997-09-11 2000-03-09 Monoklonalt antistoff som induserer apoptose

Country Status (14)

Country Link
US (1) US20030157100A1 (no)
EP (1) EP1035132B1 (no)
KR (2) KR20040106585A (no)
CN (1) CN1198845C (no)
AT (1) ATE395362T1 (no)
AU (1) AU740225B2 (no)
CA (1) CA2303072A1 (no)
DE (1) DE69839492D1 (no)
HU (1) HUP0003513A3 (no)
NO (1) NO20001238L (no)
PL (1) PL339265A1 (no)
RU (1) RU2212413C2 (no)
SK (1) SK3232000A3 (no)
WO (1) WO1999012973A1 (no)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA50708C2 (uk) * 1993-09-03 2002-11-15 Чугай Сейяку Кабусікі Кайся Моноклональне антитіло, яке має здатність розпізнавати антиген, який викликає апоптоз мієлоїдних клітин, фрагмент f(ab)2 моноклонального антитіла, гібридома ferm bp-4382
US7531643B2 (en) * 1997-09-11 2009-05-12 Chugai Seiyaku Kabushiki Kaisha Monoclonal antibody inducing apoptosis
US7696325B2 (en) 1999-03-10 2010-04-13 Chugai Seiyaku Kabushiki Kaisha Polypeptide inducing apoptosis
AU2940900A (en) * 1999-03-10 2000-09-28 Chugai Seiyaku Kabushiki Kaisha Single-stranded fv inducing apoptosis
TWI242043B (en) * 2000-03-10 2005-10-21 Chugai Pharmaceutical Co Ltd Polypeptide inducing apoptosis
WO2001079494A1 (fr) * 2000-04-17 2001-10-25 Chugai Seiyaku Kabushiki Kaisha Anticorps agonistes
US20040058393A1 (en) * 2000-04-17 2004-03-25 Naoshi Fukishima Agonist antibodies
KR100870123B1 (ko) 2000-10-20 2008-11-25 츄가이 세이야꾸 가부시키가이샤 저분자화 아고니스트 항체
AU2002210918B2 (en) 2000-10-20 2006-03-16 Chugai Seiyaku Kabushiki Kaisha Degraded agonist antibody
RU2287534C2 (ru) 2000-10-20 2006-11-20 Тугаи Сейяку Кабусики Кайся Деградированное антитело, являющееся агонистом tpo
EP1327680B1 (en) * 2000-10-20 2008-04-02 Chugai Seiyaku Kabushiki Kaisha Modified tpo agonist antibody
EP2075256A2 (en) 2002-01-14 2009-07-01 William Herman Multispecific binding molecules
AU2003271175A1 (en) 2002-10-11 2004-05-04 Masahiro Abe Cell death-inducing agent
JP2004279086A (ja) 2003-03-13 2004-10-07 Konica Minolta Holdings Inc 放射線画像変換パネル及び放射線画像変換パネルの製造方法
US20070003556A1 (en) * 2003-03-31 2007-01-04 Masayuki Tsuchiya Modified antibodies against cd22 and utilization thereof
US8613922B2 (en) 2003-04-24 2013-12-24 The University Of North Carolina At Chapel Hill Methods for inhibiting diabetic retinopathy with an antibody against integrin associated protein (IAP)
KR20060121150A (ko) * 2003-11-11 2006-11-28 추가이 세이야쿠 가부시키가이샤 인간화 항-ｃｄ47 항체
TW200530266A (en) * 2003-12-12 2005-09-16 Chugai Pharmaceutical Co Ltd Method of reinforcing antibody activity
TW200530269A (en) 2003-12-12 2005-09-16 Chugai Pharmaceutical Co Ltd Anti-Mpl antibodies
JPWO2005056602A1 (ja) * 2003-12-12 2008-03-06 中外製薬株式会社 アゴニスト活性を有する改変抗体のスクリーニング方法
CA2548929A1 (en) * 2003-12-12 2005-06-23 Chugai Seiyaku Kabushiki Kaisha Cell death inducing agent
US9493569B2 (en) 2005-03-31 2016-11-15 Chugai Seiyaku Kabushiki Kaisha Structural isomers of sc(Fv)2
EP1927367A4 (en) * 2005-05-18 2009-08-12 Univ Tokushima NOVEL PHARMACEUTICAL AGENT BASED ON AN ANTI-HLA ANTIBODY
CN101237890A (zh) 2005-06-10 2008-08-06 中外制药株式会社 含有葡甲胺的蛋白质制剂的稳定剂及其利用
CN101262885B (zh) 2005-06-10 2015-04-01 中外制药株式会社 含有sc(Fv)2的药物组合物
WO2007033221A2 (en) * 2005-09-13 2007-03-22 The General Hospital Corporation Methods and compositions for inhibition of immune responses
WO2008007755A1 (fr) * 2006-07-13 2008-01-17 Chugai Seiyaku Kabushiki Kaisha inducteur de mort cellulaire
CL2008000719A1 (es) * 2007-03-12 2008-09-05 Univ Tokushima Chugai Seiyaku Agente terapeutico para cancer resistente a agentes quimioterapeuticos que comprende un anticuerpo que reconoce hla de clase i como ingrediente activo; composicion farmaceutica que comprende dicho anticuerpo; y metodo para tratar cancer resistente a
SI4160212T1 (sl) 2008-01-15 2024-06-28 The Board Of Trustees Of The Leland Stanford Junior University Označevalci matičnih celic akutne mieloične levkemije
PT3056515T (pt) * 2008-01-15 2019-07-19 Univ Leland Stanford Junior Métodos para manipulação da fagocitose mediada por cd47
US8951527B2 (en) 2008-08-07 2015-02-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Radioprotectants targeting thrombospondin-1 and CD47
BR112014019331A2 (pt) * 2012-02-06 2022-07-12 Inhibrx Inc anticorpos para cd47 e métodos de uso desses
SG11201504469XA (en) 2012-12-12 2015-07-30 Vasculox Inc Therapeutic cd47 antibodies
US9221908B2 (en) 2012-12-12 2015-12-29 Vasculox, Inc. Therapeutic CD47 antibodies
JP6885606B2 (ja) 2015-09-18 2021-06-16 アーチ オンコロジー, インコーポレイテッドArch Oncology, Inc. 治療用ｃｄ４７抗体
EP3484448A4 (en) 2016-07-13 2020-04-01 President and Fellows of Harvard College MIMETIC SCAFFOLDS OF CELLS HAVING ANTIGEN AND METHODS OF PREPARING AND USING THEM
WO2018075960A1 (en) 2016-10-21 2018-04-26 Tioma Therapeutics, Inc. Therapeutic cd47 antibodies
AR113862A1 (es) 2017-12-01 2020-06-17 Seattle Genetics Inc Anticuerpos anti-cd47 y sus usos para tratar cáncer
CN110066336B (zh) * 2019-05-12 2021-11-09 杭州科兴生物科技有限公司 抗cd47单克隆抗体、片段及其医药用途
IL312302A (en) 2021-10-28 2024-06-01 Lyell Immunopharma Inc Methods for creating cells
WO2024077174A1 (en) 2022-10-05 2024-04-11 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2150262C (en) * 1992-12-04 2008-07-08 Kaspar-Philipp Holliger Multivalent and multispecific binding proteins, their manufacture and use
UA50708C2 (uk) * 1993-09-03 2002-11-15 Чугай Сейяку Кабусікі Кайся Моноклональне антитіло, яке має здатність розпізнавати антиген, який викликає апоптоз мієлоїдних клітин, фрагмент f(ab)2 моноклонального антитіла, гібридома ferm bp-4382
US6719972B1 (en) * 1994-06-03 2004-04-13 Repligen Corporation Methods of inhibiting T cell proliferation or IL-2 accumulation with CTLA4- specific antibodies
US5885574A (en) * 1994-07-26 1999-03-23 Amgen Inc. Antibodies which activate an erythropoietin receptor
WO1997032601A1 (fr) * 1996-03-06 1997-09-12 Chugai Seiyaku Kabushiki Kaisha Procede de criblage de substances induisant l'apoptose
US7531643B2 (en) * 1997-09-11 2009-05-12 Chugai Seiyaku Kabushiki Kaisha Monoclonal antibody inducing apoptosis
US7696325B2 (en) * 1999-03-10 2010-04-13 Chugai Seiyaku Kabushiki Kaisha Polypeptide inducing apoptosis

Also Published As

Publication number Publication date
KR20040106585A (ko) 2004-12-17
HUP0003513A2 (hu) 2001-02-28
CN1276798A (zh) 2000-12-13
AU9002898A (en) 1999-03-29
EP1035132B1 (en) 2008-05-14
PL339265A1 (en) 2000-12-04
WO1999012973A1 (fr) 1999-03-18
NO20001238L (no) 2000-05-11
DE69839492D1 (de) 2008-06-26
EP1035132A1 (en) 2000-09-13
CN1198845C (zh) 2005-04-27
RU2212413C2 (ru) 2003-09-20
SK3232000A3 (en) 2000-09-12
CA2303072A1 (en) 1999-03-18
AU740225B2 (en) 2001-11-01
US20030157100A1 (en) 2003-08-21
KR20010023866A (ko) 2001-03-26
HUP0003513A3 (en) 2004-05-28
ATE395362T1 (de) 2008-05-15
EP1035132A4 (en) 2005-02-09

Similar Documents

Publication Publication Date Title
NO20001238L (no) Monoklonalt antistoff som induserer apoptose
FI960567A0 (fi) Monoklonaalinen vasta-aine, joka indusoi apoptoosin
ATE318147T1 (de) Spezifische monoklonale antikörperfür die extrazelluläre domäne von protasta-spezifischem membranantigen
ATE123652T1 (de) Antigene.
DK1565489T3 (da) Internaliserende antistoffer specifikke for RAAG10-celleoverflademålet
PT921395E (pt) Ensaio para medicao de fragmentos de proteina em meios biologicos
ATE177754T1 (de) Fragmente von prion proteinen.
FI955798A0 (fi) Terapeuttiset vasta-ainefrangmentit
ES2133738T3 (es) Metodo para cuantificar lbp en fluidos corporales.
DK1167389T3 (da) Antistoffer mod SEMP1-proteinet, fremgangsmåde til fremstilling heraf samt anvendelse deraf
ATE128738T1 (de) Verfahren zum schnellen und empfindlichen nachweis von igm-antikörpern gegen retrovirale antigene.
EA200200974A1 (ru) Моноклональные антитела к рецептору лпнп человека, их получение и применение
FI973484A (fi) Menetelmä immuunivasteen stimuloimiseksi
ATE202116T1 (de) Antikörperklassenspezifisches entstörungsreagenz
ATE171473T1 (de) Humanisierte monoklonale antikörper gegen humanes interleukin - 4
ATE206621T1 (de) Il-8 antagonisten zur behandlung von asthma
DE59505585D1 (de) Antigene und Antikörper zum Nachweis von Kollagen I
BR9903250A (pt) Antìgenos e imunoanálises para diagnóstico da doença de chagas.
CY1106349T1 (el) Συστηματα ανιχνευσης ανοσοπροσδιορισμου ιικου αντιγονου ηπατιτιδας c
PT744027E (pt) Utilizacao de metodos para identificar oligopeptidos de sinal hidrofilicos
ATE160359T1 (de) Antigene regionen von tumorfreigestzten partikeln (tlp) komplexen und antikörper die sie erkennen.
DE69132144D1 (de) Menschliche phospholipase aktivierender proteinteil
KR100310413B1 (ko) 인간의자연형lgM항체
DE69533904D1 (de) Chemische Modifikation von Antikörpern und Antigenen
ES2013665A6 (es) Procedimiento para preparar un anticuerpo monoclonal humano y metodo de uso.